Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2024 06:00 ET | Source: Liquidia Corporation

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.